Floatz logo

Cediranib

Endometrial Clear Cell Adenocarcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Endometrial Clear Cell Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Floor Backes, MD
Phase 3BB
Dasatinib
National Cancer Institute (NCI)
Phase 2B
Bms-907351
National Cancer Institute (NCI)
Phase 2B
Doxycycline
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC

View all 11 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →